Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Payables (2023 - 2025)

Mangoceuticals (MGRX) has disclosed Payables for 3 consecutive years, with $416682.0 as the latest value for Q4 2025.

  • Quarterly Payables fell 57.8% to $416682.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $416682.0 through Dec 2025, down 57.8% year-over-year, with the annual reading at $416682.0 for FY2025, 57.8% down from the prior year.
  • Payables hit $416682.0 in Q4 2025 for Mangoceuticals, down from $626964.0 in the prior quarter.
  • In the past five years, Payables ranged from a high of $1.2 million in Q1 2025 to a low of $30796.0 in Q1 2023.
  • Historically, Payables has averaged $501401.4 across 3 years, with a median of $521823.0 in 2025.
  • Biggest YoY gain for Payables was 861.78% in 2025; the steepest drop was 57.8% in 2025.
  • Year by year, Payables stood at $140765.0 in 2023, then soared by 601.52% to $987501.0 in 2024, then tumbled by 57.8% to $416682.0 in 2025.
  • Business Quant data shows Payables for MGRX at $416682.0 in Q4 2025, $626964.0 in Q3 2025, and $867996.0 in Q2 2025.